Skip to main content
Fig. 1 | Cancer & Metabolism

Fig. 1

From: An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Fig. 1

Evaluation of the impact of DFO on HeLa cells. A Measurement of the effect of DFO on cell proliferation. **Indicates p < 0.01 compared to control group (one-way ANOVA followed by Tukey’s post hoc test). Cell proliferation was determined by measuring the area of the cells using the Incucyte HD imaging system. B Evaluation of OCR using a flux analyzer. 1 μM oligomycin, 0.5 μM FCCP, 1 μM antimycin, and 1 μM rotenone were added to the wells. C Metabolic phenogram. Basal OCR and ECAR rates were plotted in response to a 48-h DFO treatment in HeLa cells. The top-left corner of the figure indicates aerobic, bottom-right corner indicates glycolytic, top-right corner shows activated metabolism, and bottom-left corner shows reduced metabolism. Values represent mean ± SD. D A list of top five and bottom five upstream regulators. Presumed activated regulators are shown in brown, whereas those presumed inhibited are shown in blue. Cells were treated with 30 μM of DFO for 2 days. E Pathway ranking by IPA analysis. Reciprocal display of p-value calculated using the IPA software; magenta line is the ratio of genes included in each pathway. Cells were treated with 30 μM of DFO for 2 days

Back to article page

Cancer & Metabolism

ISSN: 2049-3002